Nature communications

Lnc-TALC increases DNA repair enzyme levels by controlling the c-Met pathway through competing with miR-20b-3p

Updated

Abstract

An unreported , lnc-TALC, is correlated with temozolomide resistance in glioblastoma.

  • lnc-TALC binds to miR-20b-3p, facilitating increased expression of c-Met associated with TMZ resistance.
  • lnc-TALC expression is regulated by a phosphorylated AKT/FOXO3 signaling pathway in TMZ-resistant GBM cells.
  • lnc-TALC enhances expression by promoting the acetylation of specific histones at the MGMT promoter.
  • In clinical patients, lnc-TALC is associated with TMZ resistance and glioblastoma recurrence.
  • lnc-TALC may represent a potential therapeutic target to address TMZ resistance in glioblastoma treatment.

Simplified

Key numbers

5.5%
5-year survival rate
Survival rate for GBM patients after diagnosis.
14.6 months
Median survival
Median survival duration for GBM patients upon diagnosis.

Full Text

What this is

  • Lnc-TALC is a long noncoding RNA identified in glioblastoma (GBM) that contributes to resistance against temozolomide (TMZ), a common chemotherapy drug.
  • The study reveals that lnc-TALC enhances the expression of O6-methylguanine-DNA methyltransferase () by modulating the c-Met signaling pathway.
  • By binding competitively with miR-20b-3p, lnc-TALC promotes expression and contributes to treatment failure in GBM patients.

Essence

  • Lnc-TALC promotes expression in TMZ-resistant glioblastoma by regulating the c-Met pathway and binding to miR-20b-3p, indicating its potential as a therapeutic target.

Key takeaways

  • Lnc-TALC is upregulated in TMZ-resistant GBM cells, where it enhances expression. This upregulation is mediated through the c-Met signaling pathway, which lnc-TALC regulates by binding to miR-20b-3p.
  • Inhibition of lnc-TALC restores sensitivity to TMZ in resistant GBM cells, suggesting that targeting lnc-TALC could improve treatment outcomes for patients with recurrent GBM.
  • Clinical samples show that lnc-TALC levels correlate with TMZ resistance and GBM recurrence, highlighting its role as a potential biomarker for treatment response.

Caveats

  • The study relies on in vitro and xenograft models, which may not fully replicate the complexity of human tumors and their microenvironments.
  • Further clinical validation is needed to establish the therapeutic potential of targeting lnc-TALC in GBM patients.

Definitions

  • lncRNA: Long noncoding RNA, a type of RNA that does not encode proteins but can regulate gene expression.
  • MGMT: O6-methylguanine-DNA methyltransferase, an enzyme involved in DNA repair that is often linked to chemotherapy resistance.

Simplified

Funding

Competing interests

The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free